Clinical trial
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT01554371
Study timeline
Study start (actual)2012-03-27Date precision: day
Registry last updated2021-02-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Malignant Solid Tumourunresolved
Breast Cancer Nos Metastatic Recurrentunresolved
Neuropathyunresolved
Interventions
EribulinDRUG · verified · RxNorm: eribulin
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
Sponsors & collaborators
University of California, San Franciscolead sponsor
Eisai Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01554371 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.